STHLM3 - Prostate Cancer Diagnostic Trial
Not Applicable
Completed
- Conditions
- Prostate Cancer
- Registration Number
- NCT03639649
- Lead Sponsor
- Karolinska Institutet
- Brief Summary
STHLM3 is a paired diagnostic trial aiming to assess whether a panel of biomarkers for prostate cancer can substantially reduce the proportion of men referred to biopsy whilst maintaining sensitivity for aggressive prostate cancer
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 58818
Inclusion Criteria
- Age 50-69
- Residential address in Stockholm County
Exclusion Criteria
- Previous Prostate Cancer Diagnosis
- Not able to comprehend inform consent material
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Number of biopsies Recorded directly after biopsy
- Secondary Outcome Measures
Name Time Method Number of Gleason Score ≥ 7 Recorded directly after biopsy Number of Gleason Score 6 Recorded directly after biopsy Number of benign Recorded directly after biopsy
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the key molecular biomarkers in the STHLM3 panel for detecting aggressive prostate cancer?
How does STHLM3's diagnostic accuracy compare to PSA testing in reducing unnecessary biopsies for prostate cancer?
Which specific biomarkers in the STHLM3 test predict aggressive prostate cancer to guide biopsy decisions?
What are the potential adverse outcomes of using STHLM3 (NCT03639649) over standard biopsy protocols in prostate cancer diagnosis?
How does STHLM3 integrate with multiparametric MRI for improved prostate cancer risk stratification and patient management?
Trial Locations
- Locations (1)
Karolinska Institutet
🇸🇪Stockholm, Sweden
Karolinska Institutet🇸🇪Stockholm, Sweden